PDA vs TB-500: A Research Comparison
Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.
Quick answer
PDA (an arginate form of BPC-157) and TB-500 (related to thymosin beta-4) are different peptides sometimes marketed for recovery. Neither has human evidence of effectiveness or FDA approval, and both raise safety and anti-doping concerns.
Both peptides lack human effectiveness evidence; they are chemically distinct. (Animal or laboratory findings only. Does not prove effects in humans.)
Two different peptides
PDA is marketed as a salt form of BPC-157. TB-500 is a synthetic fragment marketed in relation to thymosin beta-4. They are chemically distinct and should not be conflated.
Advertisement slot — inactive
Ads are not enabled until the site is editorially and technically ready.
Evidence status
Preclinical evidencePDA has no published studies of its own; BPC-157 (its parent) has a preclinical base. TB-500-type peptides likewise lack robust human effectiveness evidence.[1],[2]
No human proof
Neither PDA nor TB-500 has been shown to be safe and effective for any condition in humans.
Regulatory and anti-doping
Neither is FDA-approved. Peptides in this space are commonly prohibited in sport; athletes must check the current World Anti-Doping Agency and U.S. Anti-Doping Agency rules.[4],[5]
Frequently asked questions
Is TB-500 safer than PDA?
Neither has established human safety data, so a safety comparison cannot be made reliably.
References
3 peer-reviewed journal sources and 2 additional authoritative references. Every reference supports a specific statement above.
- [1] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
- [2] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal
- [3] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
- [4] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory
- [5] U.S. Food and Drug Administration (2025). Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA.gov, Regulatory information (compounding). View source Government / regulatory